Previous close | 158.88 |
Open | 158.00 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's range | 158.22 - 159.63 |
52-week range | 144.95 - 181.04 |
Volume | |
Avg. volume | 6,823,943 |
Market cap | 382.469B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 29.86 |
EPS (TTM) | 5.31 |
Earnings date | 23 Jan 2024 |
Forward dividend & yield | 4.76 (3.00%) |
Ex-dividend date | 20 Nov 2023 |
1y target est | 175.48 |
Johnson & Johnson's worldwide vice president for litigation said on Tuesday that the company has recently reached settlements with several law firms over their clients' claims that J&J talc products caused cancer. The settlements were reached "with a goal to facilitate our pursuit of a consensual prepackaged bankruptcy resolution," Erik Haas said on an investor call. J&J said in October that it was considering a new bankruptcy filing to resolve talc claims.
In the latest trading session, Johnson & Johnson (JNJ) closed at $158.55, marking a -0.21% move from the previous day.
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS) and Caterpillar Inc. (CAT).